<DOC>
	<DOCNO>NCT01889069</DOCNO>
	<brief_summary>This single arm , multicenter study evaluate safety , efficacy pharmacokinetics subcutaneous ( SC ) MabThera/Rituxan ( rituximab ) previously untreated patient CD20+ diffuse large B cell lymphoma ( DLBCL ) follicular lymphoma ( FL ) . Patients receive addition standard chemotherapy , induction phase study subcutaneous dos 1400 mg MabThera/Rituxan month least 4 cycle , maintenance phase subcutaneous dos 1400 mg MabThera/Rituxan every two month least 6 cycle .</brief_summary>
	<brief_title>A Study Evaluate Safety , Efficacy Pharmacokinetics MabThera/Rituxan ( Rituximab ) Patients With Diffuse Large B Cell Lymphoma Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient , age &gt; /= 18 &lt; /= 80 year time enrollment Histologically confirm , CD20+ DLBCL CD20+ follicular nonHodgkin 's lymphoma ( NHL ) grade 1 , 2 3a , accord WHO classification system Currently treat Mabthera/Rituxan intravenously ( IV ) Induction Maintenance setting , receive least one full dose MabThera/Rituxan IV , define standard full dose MabThera/Rituxan IV 375 mg/m2 administer without interruption early discontinuation ( i.e . tolerability issue ) Expectation current ability patient receive least four additional cycle treatment Induction phase six additional cycle treatment Maintenance phase ( patient follicular NHL ) An International Prognostic Index ( IPI ) score 14 IPI score 0 bulky disease , define one lesion &gt; /= 7.5 cm , Follicular Lymphoma International Prognostic Index ( FLIPI ) At least one bidimensionally measurable lesion define &gt; /=1.5 cm large dimension compute tomography ( CT ) scan Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /=3 Transformed lymphoma follicular lymphoma ( FL ) IIIB Primary central nervous system lymphoma , histologic evidence transformation Burkitt lymphoma , primary effusion lymphoma , primary mediastinal DLBCL , DLBCL testis , primary cutaneous DLBCL History malignancy Ongoing corticosteroid use &gt; 30 mg/day prednisone equivalent Inadequate renal hematologic hepatic function History severe allergic anaphylactic reaction humanize murine monoclonal antibody know sensitivity allergy murine product Contraindications individual component standard chemotherapy Other serious underlie medical condition , , Investigator 's judgement , could impair ability patient participate study Recent major surgery ( within 4 week prior dose , diagnosis ) Active hepatitis B virus ( HBV ) , active hepatitis C virus ( HCV ) infection , human immunodeficiency virus ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>